皇冠体育app

THE HAGUE - Life Partners (LSP), a Dutch venture capital firm, announced on Tuesday that it will establish a 皇冠体育app Fund, which will raise money in 皇冠体育app and to be used to assist the development of the European biotechnology market.

According to LSP, it will also sell ropean biotech company's technology to Chinese companies in the same industry. It is reported that this is the first time LSP will raise funds in 皇冠体育app.

As European institutional investors tend to invest less in risky industries such as life sciences because of strict capital requirements, European biotech companies lack money for research and development of new products.

Chinese biotech companies and research centers on the other hand have great need for European knowledge and expertise to accelerate the development of their products.

LSP founder and managing partner Martin Kleijwegt said he believes the LSP 皇冠体育app Fund is a "great business model."

"We will use the classical model of venture investment focusing on 皇冠体育app's academic centers, and make European biotechnology patents available for Chinese life science companies," Kleijwegt said.

Managing 800 million euros of assets, LSP is the largest provider of venture capital in 'life sciences' in Europe.